Home Cart Sign in  
Chemical Structure| 192642-85-6 Chemical Structure| 192642-85-6

Structure of 192642-85-6

Chemical Structure| 192642-85-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 192642-85-6 ]

CAS No. :192642-85-6
Formula : C7H6BrNO2
M.W : 216.03
SMILES Code : BrC1=CN=C(C=C1)CC(=O)O
MDL No. :MFCD09999983
InChI Key :ATKULCGQSLCGEK-UHFFFAOYSA-N
Pubchem ID :46238459

Safety of [ 192642-85-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 192642-85-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.14
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 43.48
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

50.19 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.3
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.04
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.47
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.82
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.72
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.27

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.11
Solubility 1.69 mg/ml ; 0.00783 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.68
Solubility 4.47 mg/ml ; 0.0207 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.66
Solubility 0.469 mg/ml ; 0.00217 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.88 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.65

Application In Synthesis of [ 192642-85-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 192642-85-6 ]

[ 192642-85-6 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 192642-85-6 ]
  • [ 1206968-77-5 ]
YieldReaction ConditionsOperation in experiment
80% [Example 60]tert-Butyl 4-[2-[2-(4-methanesulfonylphenoxyethyl)pyridine-5-yl]piperidine-1-carboxylate (1) 2-(5-Bromopyridin-2-yl)ethanol To a solution of (5-bromopyridin-2-yl)acetic acid (60.0 mg, 0.278 mmol) in dry tetrahydrofuran (1.4 mL) was added dropwise borane- tetrahydrofuran complex (1.06M in tetrahydrofuran, 0.34 mL, 0.361 mmol) under N2. The mixture was stirred at room temperature for 19 hours and water(5 mL)-acetic acid (5 mL) was added slowly. The mixture was concentrated under reduced pressure, the residue was poured into saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate=7/1→ethyl acetate) to give the title compound as a yellow oil (45 mg, yield 80%).1H NMR(CDCl3,400 MHz): δ= 2.98(2H, t, J=5 Hz), 3.68(1H, brs), 4.01(2H, t, J=5 Hz), 7.09(1H, d, J=8 Hz), 7.75(1H, dd, J=2 Hz, 8 Hz), 8.57(1H, d, J=2 Hz).
79% With diborane; In tetrahydrofuran; at -78 - 20℃; for 16h;Inert atmosphere; [00543] To a solution of Example 105a (2.16 g, 10.0 mmol) in dry THF (80 mL) was added slowly added BH3/THF (1.0 M, 30 mL) at -78C under nitrogen atmosphere. After addition, the mixture was allowed to stir from -78C to r.t. for 16 h. The reaction was quenched by saturated aqueous K2C03, extracted by EtOAc (50 mL*2), dried over Na2S04, filtered and concentrated. The residue was purified by silica gel chromatography (Petroleum Ether/EtOAc = 30/70) to give the desired product Example 105b (1.6 g, yield 79%) as colorless oil. LCMS [M+l]+ =202.0/204.0
51% With borane-THF; In tetrahydrofuran; at 20℃; for 4h;Inert atmosphere; To a stirred solution of 2-(5-bromopyridin-2-yl)acetic acid (2 g, 9.25 mmol) in THF (50 mL) was added BH3.THF (12 mL, 12.03 mmol, 1M in THF) drop wise at room temperature under nitrogen and stirred at same temperature for 24 h. The mixture was cooled to 0 C, quenched with water: acetic acid (10 mL, 1:1) and stirred at room temperature for 30 minutes. The reaction mixture was evaporated and resulting residue was diluted with EtOAc (50 mL). The organic layer was washed with saturated aqueous sodium bicarbonate solution and water, dried, filtered and evaporated. The crude compound was chromatographed on silica eluting with 40% EtOAc in petroleum ether affording a yellow liquid (950 mg, 51%). M/z = 202.0 (M+H)+.
Preparation of 6:2-(5-Bromopyridin-2-yl)ethanolUnder N2, a solution of 2-(5-bromopyridin-2-yl)acetic acid (5, 29.75 g) in THF (450 mL) was cooled to 0C. Borane THF complex (1 M in THF, 413.2 mL, 413.2 mmol) was added dropwise, keeping the reaction temperature below 5C. The mixture was allowed to warm to room temperature and stir for 4h. The mixture was cooled to 0C and saturated aqueous K2C03 solution (500 mL) and H20 (500 mL) were added slowly. The mixture was extracted with EtOAc (3x 500 mL). The combined organic layers were washed with brine (500 mL), dried over Na2S04 and filtered. The solvent was removed in vacuo and the residue was purified by column chromatography (silica,Heptane/EtOAc 3:7) yielding compound 6 (10.9 g, 53.9 mmol, 40% over 2 steps). 1 H- NMR (CDCI3, 300 MHz): δ 3.00 (t, 2H, CH2), 3.64 (bs, 1 H, OH), 4.03 (t, 2H, CH2), 7.10 (d, 1 H, ArH), 7.76 (dd, 1 H, ArH), 8.59 (d, 1 H, ArH).
1.09 g With borane-THF; In tetrahydrofuran; at 5 - 20℃; Commercially available 2-(5-bromopyridin-2-yl)acetic acid (1.00 g, 4.6 mmol) in tetrahydrofuran (10 mL) is cooled to 5 C. and treated dropwise over 10 minutes with borane-tetrahydrofuran complex (13.9 mL, 13.9 mmol). After stirring at room temperature for 4 hours, the reaction mixture is quenched with saturated aqueous potassium carbonate (20 mL), extracted with ethyl acetate (50 mL), dried over MgSO4, filtered, the solvent removed under reduced pressure, and the crude material purified by column chromatography on silica gel eluting with a gradient of neat heptane to neat ethyl acetate to afford the title compound (1.09 g): m/z (CI) 203 [M+H].

 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 192642-85-6 ]

Bromides

Chemical Structure| 917023-06-4

A288245 [917023-06-4]

Methyl 2-(5-bromopyridin-2-yl)acetate

Similarity: 0.92

Chemical Structure| 1382486-27-2

A213908 [1382486-27-2]

1-(5-Bromopyridin-2-yl)cyclobutanecarboxylic acid

Similarity: 0.86

Chemical Structure| 351003-02-6

A214448 [351003-02-6]

5-Bromo-2-methylnicotinic acid

Similarity: 0.86

Chemical Structure| 886365-43-1

A208080 [886365-43-1]

5-Bromo-3-methylpicolinic acid

Similarity: 0.81

Chemical Structure| 38749-90-5

A163388 [38749-90-5]

5-Bromo-2-ethylpyridine

Similarity: 0.78

Carboxylic Acids

Chemical Structure| 1382486-27-2

A213908 [1382486-27-2]

1-(5-Bromopyridin-2-yl)cyclobutanecarboxylic acid

Similarity: 0.86

Chemical Structure| 351003-02-6

A214448 [351003-02-6]

5-Bromo-2-methylnicotinic acid

Similarity: 0.86

Chemical Structure| 886365-43-1

A208080 [886365-43-1]

5-Bromo-3-methylpicolinic acid

Similarity: 0.81

Chemical Structure| 848093-05-0

A566592 [848093-05-0]

2-(5-Methylpyridin-2-yl)acetic acid

Similarity: 0.78

Chemical Structure| 30766-11-1

A635338 [30766-11-1]

5-Bromopicolinic acid

Similarity: 0.77

Related Parent Nucleus of
[ 192642-85-6 ]

Pyridines

Chemical Structure| 917023-06-4

A288245 [917023-06-4]

Methyl 2-(5-bromopyridin-2-yl)acetate

Similarity: 0.92

Chemical Structure| 1382486-27-2

A213908 [1382486-27-2]

1-(5-Bromopyridin-2-yl)cyclobutanecarboxylic acid

Similarity: 0.86

Chemical Structure| 351003-02-6

A214448 [351003-02-6]

5-Bromo-2-methylnicotinic acid

Similarity: 0.86

Chemical Structure| 886365-43-1

A208080 [886365-43-1]

5-Bromo-3-methylpicolinic acid

Similarity: 0.81

Chemical Structure| 38749-90-5

A163388 [38749-90-5]

5-Bromo-2-ethylpyridine

Similarity: 0.78